Piper Jaffray Companies set a $25.00 price target on Horizon Pharma (NASDAQ:HZNP) in a report released on Monday, September 17th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the stock. ValuEngine raised shares of Horizon Pharma from a hold rating to a buy rating in a report on Monday, July 30th. BidaskClub raised shares of Horizon Pharma from a hold rating to a buy rating in a report on Friday, July 20th. Zacks Investment Research raised shares of Horizon Pharma from a hold rating to a buy rating and set a $19.00 target price for the company in a report on Tuesday, July 10th. Stifel Nicolaus lifted their target price on shares of Horizon Pharma from $20.00 to $22.00 and gave the stock a buy rating in a report on Monday, June 18th. Finally, Cantor Fitzgerald set a $21.00 target price on shares of Horizon Pharma and gave the stock a buy rating in a report on Wednesday, August 8th. Five analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $21.92.
Shares of NASDAQ HZNP traded up $0.22 during mid-day trading on Monday, hitting $18.27. 1,083,819 shares of the stock were exchanged, compared to its average volume of 1,672,029. The firm has a market cap of $3.26 billion, a price-to-earnings ratio of 15.48, a PEG ratio of 1.24 and a beta of 1.40. The company has a current ratio of 1.70, a quick ratio of 1.63 and a debt-to-equity ratio of 2.19. Horizon Pharma has a twelve month low of $12.55 and a twelve month high of $21.25.
In other news, EVP Geoffrey M. Curtis sold 9,904 shares of Horizon Pharma stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $20.63, for a total transaction of $204,319.52. Following the transaction, the executive vice president now directly owns 28,767 shares of the company’s stock, valued at $593,463.21. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 3.90% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of HZNP. Wells Fargo & Company MN lifted its position in Horizon Pharma by 48.9% in the 1st quarter. Wells Fargo & Company MN now owns 566,951 shares of the biopharmaceutical company’s stock valued at $8,051,000 after acquiring an additional 186,210 shares in the last quarter. American Century Companies Inc. lifted its position in Horizon Pharma by 158.5% in the 1st quarter. American Century Companies Inc. now owns 706,775 shares of the biopharmaceutical company’s stock valued at $10,036,000 after acquiring an additional 433,359 shares in the last quarter. Prudential Financial Inc. lifted its position in Horizon Pharma by 265.8% in the 1st quarter. Prudential Financial Inc. now owns 277,244 shares of the biopharmaceutical company’s stock valued at $3,937,000 after acquiring an additional 201,444 shares in the last quarter. D.A. Davidson & CO. bought a new stake in Horizon Pharma in the 1st quarter valued at $143,000. Finally, Swiss National Bank lifted its position in Horizon Pharma by 2.3% in the 1st quarter. Swiss National Bank now owns 284,456 shares of the biopharmaceutical company’s stock valued at $4,039,000 after acquiring an additional 6,300 shares in the last quarter. 87.25% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
See Also: 52-Week High/Low
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.